Execution Copy

Exhibit 10.43

 

 

 

 

AMENDMENT No. 2

 

to the

 

NON-EXCLUSIVE LICENSE AGREEMENT

 

Dated 6 February 2012

 

Between

 

BIOWA, INC.

 

and

 

LONZA SALES AG

 

and

 

 

FIVE PRIME THERAPEUTICS, INC.

 

 

 

 

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

Execution Copy

THIS AMENDMENT No. 2 (this “Amendment”) is made the 17th day of April, 2018 (the
“Effective Date”)

 

 

BETWEEN

 

BIOWA, INC., a Delaware corporation, with a principal place of business at 212
Carnegie Center, Suite 400, Princeton, NJ 08540, USA (“BioWa”)

 

AND

 

LONZA SALES AG incorporated and registered in Switzerland whose registered
office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland, (“Lonza")

 

(together the “Licensor”)

 

AND

 

FIVE PRIME THERAPEUTICS, INC., a Delaware corporation with a principal place of
business at 111 Oyster Point Boulevard, South San Francisco, California 94080,
USA (“Licensee”).  

 

WHEREAS

 

A.

Licensor and Licensee entered into a Non-Exclusive License Agreement dated 6
February 2012, as amended on 6 June 2013 (hereinafter referred to as the
“Agreement”) under which (inter alia) Licensor released materials to Licensee
for the purposes of the Commercial License (all as therein defined); and.

 

B.

Licensor and Licensee now wish to amend the terms of the Agreement.

 

NOW THEREFORE in consideration of the mutual promises and covenants contained
herein and other good and valuable consideration the sufficiency of which is
acknowledged, and intending to be legally bound, it is hereby agreed by and
between the Parties to amend the Agreement as follows:

 

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

Execution Copy

1.

Capitalized terms used in this Amendment No. 2 and not otherwise defined herein
shall have the same meanings ascribed to such terms in the Agreement.  

 

2.

In accordance with Section 2.2.2 of the Agreement, Licensor hereby consents to
Licensee’s written request dated December 9, 2016 that Licensor consent to: (i)
the transfer of Transfected Cells by the Licensee to [***], a [***] (hereafter
“[***]”) at its [***] facility only, notwithstanding the fact that the Parties
understand that [***] is, as of the date of this Amendment No. 2, a Competing
Contract Manufacturer; and (ii) the sublicense to [***] at its [***] facility
only of the rights to make the Product only for the benefit of Licensee as
granted to Licensee under Section 2.1 of the Agreement. Such sub-licensing
referred to in this Amendment No. 2 shall be subject to the terms of the
Agreement, including, without limitation, Sections 2.2.3 and 2.3. Licensee shall
at all times remain responsible for the acts and omissions of [***] in
connection with such sub-licensing as set forth in Section 2.3 of the
Agreement. 

 

3.

Licensee shall pay to Lonza the initial payment of the Lonza Annual License Fee
when and as applicable, in accordance with terms set out under Section 6.3 of
the Agreement.

 

4.

Save as herein provided all other terms and conditions of the Agreement shall
remain in full force and effect.

 

[Remainder of page intentionally blank; signature page follows]

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

Execution Copy

IN WITNESS WHEREOF the Parties have caused this Amendment No. 2 to be executed
by their respective representatives thereunto duly authorised effective as of
the day and year first above written.

 

 

Signed for and on behalf of

BIOWA, INC.

../s/ Takeshi Masuda....................

 

Takeshi Masuda

TITLE:  President and CEO

 

Signed for and on behalf of

.../s/ Albert Pereda.......................

LONZA SALES AG

...Senior Legal Counsel...............  TITLE

 

 

Signed for and on behalf of

.../s/ Cordula Altekrüger...............

LONZA SALES AG

...Senior Legal Counsel...............  TITLE

 

 

 

Signed for and on behalf of

.../s/ Kevin Baker........................

FIVE PRIME THERAPEUTICS, INC.

..SVP, Development Sciences....  TITLE

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.